All news from Pulmonary Medicine

First Mouse Model of Idiopathic Pulmonary Fibrosis was Developed

The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability to fully model the disease in animals, limiting the ability to observe and understand the disease.

Now, a team of researchers from Penn Medicine has developed the first mouse model with an IPF-associated mutation, which induces scarring and other damage similar to what is observed in humans suffering from the condition. The findings are published this week in the Journal of Clinical Investigation.

Mepolizumab for COPD, FDA Panel Against the Recommendation

The US Food and Drug Administration's (FDA's) Pulmonary-Allergy Drugs Advisory Committee voted overwhelmingly not to recommend (no-16, yes-3) mepolizumab (Nucala, GlaxoSmithKline) "as add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) guided by blood eosinophil counts."

OS Benefit in NSCLC With Broad-Based Testing

In community oncology practices, where most cancer in the United States is treated, broad-based genetic testing does not offer survival advantages compared with routine genetic testing for patients with advanced non-small cell lung cancer (NSCLC), concludes a new retrospective study.

But lung cancer experts challenge this conclusion, pointing out that few of the patients who were found to have actionable mutations on broad-based genetic testing actually received targeted therapy and some received targeted therapy not matched to the mutations.

EVLP Increases Donor Organ Supply

As many as 80% of lungs from organ donors are not used, either because they are not in good enough condition to transplant, or there are doubts about their quality and there is no way to verify their condition.